JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Willette, R. N.
Right arrow Articles by Ruffolo, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Willette, R. N.
Right arrow Articles by Ruffolo, R. R., Jr.

Vol. 289, Issue 1, 48-53, April 1999

In Vitro and In Vivo Characterization of Intrinsic Sympathomimetic Activity in Normal and Heart Failure Rats

Robert N. Willette, Nambi Aiyar, Tian-Li Yue, Marcus P. Mitchell, Jyoti Disa, Barbara L. Storer, Diane P. Naselsky, Jeffery M. Stadel, Eliot H. Ohlstein and Robert R. Ruffolo, Jr.

Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania

Clinical studies conducted with carvedilol suggest that beta -adrenoceptor antagonism is an effective therapeutic approach to the treatment of heart failure. However, many beta -adrenoceptor antagonists are weak partial agonists and possess significant intrinsic sympathomimetic activity (ISA), which may be problematic in the treatment of heart failure. In the present study, the ISAs of bucindolol, xamoterol, bisoprolol, and carvedilol were evaluated and compared in normal rats [Sprague-Dawley (SD)], in rats with confirmed heart failure [spontaneously hypertensive heart failure (SHHF)], and in isolated neonatal rat cardiomyocytes. At equieffective beta 1-adrenolytic doses, the administration of xamoterol and bucindolol produced a prolonged, equieffective, and dose-related increase in heart rate in both pithed SD rats (ED50 = 5 and 40 µg/kg, respectively) and SHHF rats (ED50 = 6 and 30 µg/kg, respectively). The maximum effect of both compounds in SHHF rats was approximately 50% of that observed in SD rats. In contrast, carvedilol and bisoprolol had no significant effect on resting heart rate in the pithed SD or SHHF rat. The maximum increase in heart rate elicited by xamoterol and bucindolol was inhibited by treatment with propranolol, carvedilol, and betaxolol (beta 1-adrenoceptor antagonist) but not by ICI 118551 (beta 2-adrenoceptor antagonist) in neonatal rat. When the beta -adrenoceptor-mediated cAMP response was examined in cardiomyocytes, an identical partial agonist/antagonist response profile was observed for all compounds, demonstrating a strong correlation with the in vivo results. In contrast, GTP-sensitive ligand binding and tissue adenylate cyclase activity were not sensitive methods for detecting beta -adrenoceptor partial agonist activity in the heart. In summary, xamoterol and bucindolol, but not carvedilol and bisoprolol, exhibited direct beta 1-adrenoceptor-mediated ISA in normal and heart failure rats.

0022-3565/99/2891-0048$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
S. B. Liggett, J. Mialet-Perez, S. Thaneemit-Chen, S. A. Weber, S. M. Greene, D. Hodne, B. Nelson, J. Morrison, M. J. Domanski, L. E. Wagoner, et al.
A polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure
PNAS, July 25, 2006; 103(30): 11288 - 11293.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. Maack, M. Bohm, L. Vlaskin, E. Dabew, K. Lorenz, H.-J. Schafers, M. J. Lohse, and S. Engelhardt
Partial Agonist Activity of Bucindolol Is Dependent on the Activation State of the Human {beta}1-Adrenergic Receptor
Circulation, July 22, 2003; 108(3): 348 - 353.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Bristow
Antiadrenergic Therapy of Chronic Heart Failure: Surprises and New Opportunities
Circulation, March 4, 2003; 107(8): 1100 - 1102.
[Full Text] [PDF]

Home page
 CirculationHome page
P. Andreka, N. Aiyar, L. C. Olson, J. Q. Wei, M. S. Turner, K. A. Webster, E. H. Ohlstein, and N. H. Bishopric
Bucindolol Displays Intrinsic Sympathomimetic Activity in Human Myocardium
Circulation, May 21, 2002; 105(20): 2429 - 2434.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Ponicke, I. Heinroth-Hoffmann, and O.-E. Brodde
Differential Effects of Bucindolol and Carvedilol on Noradenaline-Induced Hypertrophic Response in Ventricular Cardiomyocytes of Adult Rats
J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 71 - 76.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Bundkirchen, K. Brixius, B. Bolck, and R. H. G. Schwinger
Bucindolol Exerts Agonistic Activity on the Propranolol-Insensitive State of beta 1-Adrenoceptors in Human Myocardium
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 794 - 801.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Packer, A. J.S. Coats, M. B. Fowler, H. A. Katus, H. Krum, P. Mohacsi, J. L. Rouleau, M. Tendera, A. Castaigne, E. B. Roecker, et al.
Effect of Carvedilol on Survival in Severe Chronic Heart Failure
N. Engl. J. Med., May 31, 2001; 344(22): 1651 - 1658.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.